Know Cancer

or
forgot password

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III


Phase 3
15 Years
65 Years
Not Enrolling
Both
Leukemia, Lymphocytic, Acute

Thank you

Trial Information

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III


Comparison between two autograf therapeutic strategies in high risk patients Ramdomised
comparison between maintenance treatment with or not interferon alpha 2 a

Inclusion Criteria


Inclusion Criteria

- ALL high risk or low risk or lymphoblastic lymphoma

- age 15-55 years old

- informed consent signed

Exclusion Criteria:

- patients previously treated with a chemotherapy or alpha-interferon

- ALL 3 (burkitt like)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall survival

Outcome Time Frame:

time to death

Principal Investigator

Norbert IFRAH, Pr

Investigator Role:

Principal Investigator

Investigator Affiliation:

Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

GOELAL02

NCT ID:

NCT00483132

Start Date:

September 1994

Completion Date:

April 2002

Related Keywords:

  • Leukemia, Lymphocytic, Acute
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Name

Location